Riya Singhal
Affiliation(s):
None
Background: Xanthine oxidase (XO) inhibition is a cornerstone of hyperuricemia and gout management, yet the clinical utility of available synthetic inhibitors is constrained by hypersensitivity, cardiovascular signals, renal dosing limitations, and flare risk at initiation. The buried molybdenum–pterin cofactor and narrow substrate channel pose nontrivial constraints on scaffold design, which likely contribute to the small number of approved agents despite the global burden of urate crystal–mediated disease. There is a persistent need for safer, mechanistically informed, nonsynthetic agents that could be deployed as monotherapy, in lowdose combinations, or in dosesparing strategies alongside established uratelowering therapies.
Objective: To identify, prioritize, and experimentally validate nonsynthetic XO inhibitor candidates using an integrated in silico–to–in vitro workflow, with a focus on cofactors and phytochemical scaffolds capable of engaging the molybdenum–pterin environment.
Methods: A virtual screen of clinically relevant compounds was performed in Mcule using structurebased docking at the XO active site, followed by Chemmine Tools–based similarity clustering to enrich for pteridinelike small molecules. ADMETguided filtering prioritized candidates with favorable predicted safety and druglikeness. Shortlisted agents (folic acid, niacin, niacinamide; Moringa oleifera, Curcuma longa, Zingiber officinale) and allopurinol were evaluated in a benchtop XO assay in which xanthine is converted to uric acid; uric acid production was monitored semiquantitatively using commercially available colorimetric strips. Nine subgroups (three inhibitor classes × three doses) were assessed across multiple time points, and relative strip intensity was analyzed using the Kruskal–Wallis test followed by rankbased trend inspection to characterize inhibition patterns.
Findings: Multiple nonsynthetic agents produced reproducible reductions in uric acid–associated color intensity versus uninhibited controls across four prespecified groups: synthetic comparators, vitamin B analogs, natural products, and nonsynthetic combinations. Within the vitamin B group (folic acid, niacin, niacinamide), folic acid consistently showed the greatest semiquantitative inhibition; within the natural group (Moringa oleifera, Curcuma longa, Zingiber officinale), Moringa oleifera outperformed turmeric and ginger, in line with emerging XOinhibitory data for Moringa extracts. For each of the three monotherapy groups (synthetic, vitamin B, natural), global withingroup nonparametric comparisons did not reach conventional statistical significance, reflecting small sample sizes and semiquantitative readouts, yet rankbased profiles demonstrated coherent, concentrationdependent inhibitory trends in favor of folic acid and Moringa. In a fourth group, constructed from the best performers of each class, exploratory lowdose combination conditions (allopurinol + folic acid, allopurinol + Moringa, and folic acid + Moringa) yielded the most favorable inhibition profiles in the panel, suggesting potential dosesparing or additive effects relative to singleagent exposures.
Summary: Coupling Mculeguided docking with Chemmine similarity filtering and a simple colorimetric XO assay provides a pragmatic discovery and prioritization pipeline for lowtoxicity XOactive agents. The identification of mechanistically plausible nonsynthetic leads—particularly folic acid and Moringa oleifera—and their promising behavior both as monotherapies and in exploratory lowdose combinations with allopurinol supports further kinetic, crystallographic, and in vivo work. These data align with evolving interest in lowdose and combination uratelowering strategies and may ultimately contribute to broader, safer therapeutic options for gout and other crystalinduced disorders.